Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients

Código QR

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients

József Attila Szász,1,2 Károly Orbán-Kis,1 Viorelia Adelina Constantin,2,3 Csongor Péter,1 István Bíró,1 István Mihály,1,2 Kinga Szegedi,2 Antal Balla,2 Szabolcs Szatmári1,2 1Uni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Szász JA, Orbán-Kis K, Constantin VA, Péter C, Bíró I, Mihály I, Szegedi K, Balla A, Szatmári S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Parkinson’s disease levodopa dopamin agonist Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b5401913058d40abbaf589a699d9b6ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
por: Szász JA, et al.
Publicado: (2019)

Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006)

A review of ropinirole prolonged release in Parkinson’s disease
por: Muhammad M Nashatizadeh, et al.
Publicado: (2009)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin VA, et al.
Publicado: (2020)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)

Comparación farmacocinética de Sinemetây Grifoparkinâ (levodopa/carbidopa 250/25 mg) en pacientes con enfermedad de Parkinson avanzada: un estudio con dosis única
por: Chaná C,Pedro, et al.
Publicado: (2003)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
por: Modugno N, et al.
Publicado: (2020)

Adverse drug reaction suggests by a clinical vignette
por: Finestone AJ
Publicado: (2011)

The Retinal Posterior Pole in Early Parkinson’s Disease: A Fundus Perimetry and SD-OCT Study
por: Cesareo M, et al.
Publicado: (2021)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller T
Publicado: (2018)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman DY, et al.
Publicado: (2018)

Síndrome neuroléptico maligno-like como complicación en enfermedad de Parkinson: Desenlace fatal. Reporte de un caso y revisión de la literatura
por: Salinas S,Carlos, et al.
Publicado: (2014)

Pharmacological methods of therapy in Parkinson’s disease
por: Y. N. Bykov, et al.
Publicado: (2016)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu N, et al.
Publicado: (2018)

Relationships between Freezing of Gait Severity and Cognitive Deficits in Parkinson’s Disease
por: Jamie L. Scholl, et al.
Publicado: (2021)

Neuropsychiatric symptoms in untreated Parkinson’s disease
por: Szatmari S, et al.
Publicado: (2017)

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
por: A Ahmadi Ahangar, et al.
Publicado: (2002)

Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
por: Cuevas,José Luis, et al.
Publicado: (2013)

Síndrome de piernas inquietas (enfermedad de Willis-Ekbom): seguimiento a largo plazo de una serie de pacientes
por: Miranda C,Marcelo, et al.
Publicado: (2016)

Diagnóstico precoz de enfermedad de Parkinson: neurospect del transportador de Dopamina
por: Díaz,Fernando, et al.
Publicado: (2002)

Systematic review on strength training in Parkinson’s disease: an unsolved question
por: Ramazzina I, et al.
Publicado: (2017)

2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

Severo edema inducido por la terapia dopaminérgica en la enfermedad de Parkinson. Caso clínico
por: Miranda C.,Marcelo, et al.
Publicado: (2017)

The role of rasagiline in the treatment of Parkinson’s disease
por: Julie Leegwater-Kim, et al.
Publicado: (2010)

Using Graphene-Based Biosensors to Detect Dopamine for Efficient Parkinson’s Disease Diagnostics
por: Małgorzata Kujawska, et al.
Publicado: (2021)

Cytological and cytometric analysis of oral mucosa in patients with Alzheimer’s and Parkinson’s disease
por: Kose Ozlece H, et al.
Publicado: (2018)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino C, et al.
Publicado: (2016)

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
por: R. Matthew Hutchison, et al.
Publicado: (2021)

Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment
por: Kasemsap N, et al.
Publicado: (2016)

Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson’s disease
por: Mao CJ, et al.
Publicado: (2017)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Retraction]
por: Hinz M, et al.
Publicado: (2021)

Sensory attenuation in Parkinson’s disease is related to disease severity and dopamine dose
por: Noham Wolpe, et al.
Publicado: (2018)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: José-Francisco Rocha, et al.
Publicado: (2021)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel AB, et al.
Publicado: (2018)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

Parkinson’s Disease-Associated Melanin Steal [Retraction]
por: Hinz M, et al.
Publicado: (2021)

Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
por: Zhang H, et al.
Publicado: (2019)